scholarly journals Cystatin C allows to detect early progression of chronic kidney disease in patients with acute decompensation of chronic heart failure

2018 ◽  
Vol 20 (12) ◽  
pp. 30-34
Author(s):  
V.V. Davydov ◽  
◽  
E.L. Arechina ◽  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Chronic Heart Failure ◽  
Kidney Disease ◽  
Cystatin C ◽  
Early Progression ◽  
Acute Decompensation

scholarly journals Prevention of chronic kidney disease progression in patients with acute decompensation of chronic heart failure

2019 ◽  
Vol 24 (3) ◽  
pp. 76-81
Author(s):  
V. V. Davydov ◽  
E. L. Arekhina
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Chronic Heart Failure ◽  
Kidney Disease ◽  
Serum Creatinine ◽  
Prevention Program ◽  
Ckd Progression ◽  
Acute Decompensation ◽  
Group 2 ◽  
Group 1

Aim.To assess the efficiency of the program of prevention of chronic kidney disease (CKD) progression in patients with acute decompensation of chronic heart failure (CHF). The program included the use of nitrendipine, a calcium channel antagonist, and the replacement of single intravenous bolus dosing of furosemide with a prolonged intravenous infusion in the early stage of the disease.Material and methods.One hundred twenty five patients with decompensation of CHF were examined and divided into 2 groups. Group 1 received standard therapy. In the group 2, an additional prevention program was carried out. The criterion of CKD progression was the change in glomerular filtration rate (GFR) in accordance with the KDIGO guidelines (2012). GFR was calculated by two methods: serum creatinine and cystatin C levels. The parameters were monitored and compared with baseline levels at admission to the hospital and on the 10th day of therapy. For the initial level was taken the patient’s GFR, calculated by the serum creatinine level prior to the present hospitalization on the background of a satisfactory condition.Results.At admission to the hospital, in group 1 CKD progression was established in 33,3% of patients, in group 2 — in 29,3%. On the 10th day, CKD progression was noted in 47,4% of patients in group 1, in group 2 — in 23,4%.Conclusion.The prevention program allows to reduce the number of cases of CKD progression in patients with decompensation of CHF by 2 times.

SARCOPENIA AS THE REASON OF HYPODIAGNOSTICS OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH CHRONIC HEART FAILURE

2020 ◽  
pp. 121-126
Author(s):  
Н. И. Гуляев ◽  
И. М. Ахметшин ◽  
А. В. Гордиенко ◽  
В. В. Яковлев
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Chronic Heart Failure ◽  
Kidney Disease ◽  
Cystatin C ◽  
Kinetic Method ◽  
Absolute Difference ◽  
Composite Body ◽  
Patients With Heart Failure ◽  
Total Fat

Цель работы - сопоставление показателей СКФ, рассчитанных на основании сывороточных концентраций креатинина и цистатина С у 86 пациентов 60-92 лет (средний возраст - 75±7 лет) с ХСН и саркопенией. СКФ рассчитывали по формулам на основе креатинина ( CKD-EPIСr ), цистатина С ( CKDEPIСys ) крови и обоих маркеров ( CKD-EPIСr-Cys ). Концентрацию цистатина С в сыворотке крови определяли иммунотурбидиметрическим методом, креатинина - Яффе-кинетическим методом. У всех больных исследован композитный состав тела с помощью двуэнергетической рентгеновской абсорбциометрии с расчетом индекса саркопении (по критериям FNIH, 2014 г.) и измерена общая жировая масса. Проведены тест с 6-минутной ходьбой, оценка по шкале ШОКС, трансторакальная эхо-КГ с измерением конечного диастолического размера, конечного систолического размера, ФВ ЛЖ, массы миокардаЛЖ, индекса массы миокарда ЛЖ, показателей диастолической функции ЛЖ. В зависимости от критериев диагностики саркопении пациенты были разделены на две группы: 1-я ( n =42) - сочетание ХСН и саркопении; 2-я ( n =44) - ХСН без саркопении. У больных с ХСН и саркопенией наблюдали переоценку СКФ, рассчитанной по уровню креатинина, на 23% (абсолютная разница - более 18 мл/мин на 1,73 м) по сравнению с СКФ, оцененной по уровню цистатина С . У больных с ХСН и саркопенией при использовании сывороточной концентрации креатинина имеет место гиподиагностика выраженности хронической болезни почек. В этой связи при наличии признаков саркопении для расчета СКФ рекомендуется использовать формулу CKD-EPIСys . The purpose of the research is comparison of glomerular filtration rate calculated on the basis of serum concentrations of creatinine and cystatin C in patients with chronic heart failure and sarcopenia. In this research 86 patients with chronic heart failure and sarcopenia aged 60 to 92 years (mean age 75±7 years) were examined. GFR calculation was determined using formulas based on creatinine ( CKD-EPIC ), cystatin C ( CKD-EPICys ) in blood and both markers ( CKD-EPICr-Cys ). The concentration of cystatin C in blood serum was determined by the immunoturbidimetric method, and creatinine by the Jaffe kinetic method. Composite body composition was studied in all patients using dual-energy X -ray absorptiometry with calculation of the sarcopenia index (according to FNIH criteria, 2014) and measurement of total fat mass. A test with a 6-minute walk, an assessment according to the SHOKS scale (clinical condition assessment scale for CHF), transthoracic echocardiography with the measurement of EDD, ESD, LVEF, LVМ, LVIM, indicators of LV diastolic function was performed. Depending on the diagnostic criteria for sarcopenia, patients were divided into 2 groups: the first - a combination of heart failure and sarcopenia; the second - CHF without sarcopenia. In patients with CHF and sarcopenia, GFR was reassessed as calculated by the creatinine level by 23 % (the absolute difference is more than 18 ml/min/1,73 m) compared with GFR estimated by the level of cystatin C . In patients with heart failure and sarcopenia, when using a serum concentration of creatinine, there is a hypodiagnostics of the severity of chronic kidney disease. In this regard, if there are signs of sarcopenia, it is recommended to use the formula CKD-EPICys to calculate GFR.

Abstract 17220: Effects of the Oral Adsorbent of AST-120 in Patients with both Chronic Heart Failure and Chronic Kidney Disease

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Miki Imazu ◽  
Masanori Asakura ◽  
Takuya Hasegawa ◽  
Hiroshi Asanuma ◽  
Shin Ito ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Chronic Heart Failure ◽  
Kidney Disease ◽  
Diastolic Dysfunction ◽  
Uremic Toxins ◽  
Control Group ◽  
Blood Levels ◽  
Uremic Toxin ◽  
Oral Adsorbent

Background: One of uremic toxins, indoxyl sulfate (IS) is related to the progression of chronic kidney disease (CKD) and the worse cardiovascular outcomes. We have previously reported the relationship between IS levels and the severity of chronic heart failure (CHF), but the question arises as to whether the treatment of uremic toxin is beneficial in patients with CHF. This study aimed to elucidate whether the treatment with the oral adsorbent which reduces uremic toxin improved the cardiac function of the patients with CHF. Methods: First of all, we retrospectively enrolled 49 patients with both CHF and stage ≤3 CKD in our institute compared with the healthy subjects without CHF or CKD in the resident cohort study of Arita. Secondly, we retrospectively enrolled 16 CHF outpatients with stage 3-5 CKD. They were treated with and without the oral adsorbent of AST-120 for one year termed as the treatment and control groups, respectively. We underwent both blood test and echocardiography before and after the treatment. Results: First of all, among 49 patients in CHF patients, plasma IS levels increased to 1.38 ± 0.84 μg/ml from the value of 0.08 ± 0.06 μg/ml in Arita-cho as a community-living matched with gender and eGFR of CHF patients. We found both fractional shortening (FS) and E/e’, an index of diastolic function were decreased (25.0 ± 12.7%) and increased (13.7 ± 7.5), respectively in CHF patients compared with the value of FS and E/e’ in Arita-cho (FS: 41.8 ± 8.3%, E/e’: 8.8 ± 2.1). Secondly, in the treatment group, the plasma IS levels and the serum creatinine and brain natriuretic peptide levels decreased (1.40 ± 0.17 to 0.92 ± 0.15 μg/ml; p<0.05, 1.91 ± 0.16 to 1.67 ± 0.12 mg/dl; p<0.05, 352 ± 57 to 244 ± 49 pg/ml; p<0.05, respectively) and both FS and E/e’ were improved following the treatment with AST-120 (28.8 ± 2.8 to 32.9 ± 2.6%; p<0.05, 18.0 ± 2.0 to 11.8 ± 1.0; p<0.05). However, these parameters did not change in the control group. Conclusions: The treatment to decrease the blood levels of uremic toxins improved not only renal dysfunction but cardiac systolic and diastolic dysfunction in patients with chronic heart failure. Oral adsorbents might be a new treatment of heart failure especially with diastolic dysfunction.

Do levels of C-reactive protein and blood protein spectrum components influence the clinical course of chronic heart failure combined with chronic kidney disease?

2016 ◽  
Vol 17 (2) ◽  
pp. 75-81
Author(s):  
A.A. Nasybullina ◽  
◽  
O.V. Bulashova ◽  
E.V. Khazova ◽  
V.M. Gazizyanova ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Chronic Heart Failure ◽  
Kidney Disease ◽  
Clinical Course ◽  
Blood Protein ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Protein Spectrum

Renal arterial pulsatility predicts progression of chronic kidney disease in chronic heart failure patients

2013 ◽  
Vol 167 (6) ◽  
pp. 3050-3051 ◽  
Author(s):  
Mariantonietta Cicoira ◽  
Luca Conte ◽  
Andrea Rossi ◽  
Stefano Bonapace ◽  
Giulia D'Agostini ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Chronic Heart Failure ◽  
Kidney Disease ◽  
Heart Failure Patients

scholarly journals Prognostic Importance of Chronic Kidney Disease in Japanese Patients With Chronic Heart Failure

2008 ◽  
Vol 72 (2) ◽  
pp. 173-178 ◽  
Author(s):  
Nobuyuki Shiba ◽  
Mika Matsuki ◽  
Jun Takahashi ◽  
Tomohiro Tada ◽  
Jun Watanabe ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Chronic Heart Failure ◽  
Kidney Disease ◽  
Japanese Patients ◽  
Prognostic Importance

scholarly journals Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure

2017 ◽  
Vol 21 (5) ◽  
pp. 858-865 ◽  
Author(s):  
Mari Katsumata ◽  
Nobuhito Hirawa ◽  
Koichiro Sumida ◽  
Minako Kagimoto ◽  
Yosuke Ehara ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Chronic Heart Failure ◽  
Kidney Disease
Sign in / Sign up

Export Citation Format

Share Document